BW
GILD icon

Basepoint Wealth’s Gilead Sciences GILD Stock Holding History

Basepoint Wealth’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56K Buy
443
+9
+2% +$1.19K 0.03% 212
2026
Q1 		$60.4K Buy
434
+3
+0.7% +$420 0.03% 196
2025
Q4 		$52.9K Buy
+431
New +$52.4K 0.03% 207
2024
Q2 		– Sell
-3,319
Closed -$243K – 113
2024
Q1 		$243K Sell
3,319
-3,472
-51% -$267K 0.18% 102
2023
Q4 		$550K Sell
6,791
-3,812
-36% -$297K 0.44% 56
2023
Q3 		$795K Sell
10,603
-26
-0.2% -$2K 0.65% 38
2023
Q2 		$819K Buy
10,629
+44
+0.4% +$3.51K 0.68% 39
2023
Q1 		$878K Buy
10,585
+217
+2% +$18K 0.73% 36
2022
Q4 		$890K Sell
10,368
-224
-2% -$17.7K 0.79% 32
2022
Q3 		$653K Buy
10,592
+2,975
+39% +$188K 0.7% 40
2022
Q2 		$471K Buy
+7,617
New +$472K 0.49% 50

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Basepoint Wealth's GILD Position: Q2 2026 in Review

Basepoint Wealth increased its Gilead Sciences (GILD) stake by 2.1% in Q2 2026, buying an estimated $1.19K and bringing the position to 443 shares worth $56K. The position accounts for 0.03% of the portfolio, ranked #212.

Basepoint Wealth first reported a position in GILD in Q2 2022 and has held it in 11 quarters since. The position peaked at $890K in Q4 2022. 2,281 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Basepoint Wealth held 443 shares of Gilead Sciences worth $56K as of Q2 2026.
  • Basepoint Wealth bought 9 Gilead Sciences shares in Q2 2026, an estimated $1.19K.
  • Gilead Sciences made up 0.03% of Basepoint Wealth's portfolio in Q2 2026, its #212 holding.
  • Basepoint Wealth first reported a position in Gilead Sciences in Q2 2022 and has held it in 11 quarters since.
  • Basepoint Wealth's Gilead Sciences position peaked at $890K in Q4 2022.
  • 2,281 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Basepoint Wealth's 13F filing for Q2 2026, filed 10 Aug 2026.